Literature DB >> 8648849

High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European Benign Prostatic Hyperplasia Study Group.

J J de la Rosette1, M J de Wildt, K Höfner, S S Carter, F M Debruyne, A Tubaro.   

Abstract

PURPOSE: We documented the results of high energy transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia.
MATERIALS AND METHODS: We evaluated 116 patients following transurethral microwave thermotherapy according to symptom scores, transrectal ultrasound, free voiding and pressure-flow study parameters.
RESULTS: Significant improvement was noted in all objective and subjective parameters. Moreover, cavities in the prostatic urethra were observed in almost 40% of the patients.
CONCLUSIONS: High energy transurethral microwave thermotherapy is an effective therapy for benign prostatic hyperplasia. Patients with larger prostates and moderate to severe bladder outlet obstruction seem to be the best candidates for this higher energy thermotherapy protocol, although morbidity is increased.

Entities:  

Mesh:

Year:  1996        PMID: 8648849

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Transurethral microwave thermotherapy in benign prostatic hyperplasia.

Authors:  P Minnee; F M Debruyne; J J de la Rosette
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

Review 2.  Transurethral hot water balloon thermoablation.

Authors:  J J de la Rosette; G Alivizatos; M P Laguna
Journal:  Curr Urol Rep       Date:  2001-08       Impact factor: 3.092

3.  [S2e guideline of the German urologists: Instrumental treatment of benign prostatic hyperplasia].

Authors:  T Bschleipfer; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; K Höfner
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

Review 4.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.